Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 29, 2026, 11:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,051 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: No Therapy 6 Weeks Clear all
Completed No phase listed Observational

Evaluation of the Association Between Genetic Load and Response to Anti-VEGF Therapy in AMD Patients

NCT01644513
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
Not listed
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
55 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Sep 29, 2026, 11:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bitter Taste and Weight Loss in Women

NCT01856660
View directory record Official record
Conditions
Obesity, Weight Loss
Interventions
Low-Carbohydrate Diet, Low-fat Diet
Behavioral
Lead sponsor
Rutgers University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Sep 29, 2026, 11:15 PM EDT
Completed Not applicable Interventional

Imaging Study on Halcyon 4.0 System for Patients Receiving Radiation Therapy

NCT05427214
View directory record Official record
Conditions
Brain Cancer, Head and Neck Cancer, Lung Cancer, Gastric Cancer, Ovarian Cancer, Colon Cancer
Interventions
Halcyon 4.0 system
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Sep 29, 2026, 11:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparing the Efficacy of a Dual-Frequency LLLT Device With a Sham Device as a Therapy for Adipose Tissue Loss

NCT03811093
View directory record Official record
Conditions
Obesity, Body Weight, Fat Burn, Cellulite, Abdominal Fat, Adipose Tissue Atrophy
Interventions
Care as Usual Group, Sham Group
Device
Lead sponsor
IR Technology, LLC
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Hixson, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Sep 29, 2026, 11:15 PM EDT
Completed Phase 2 Interventional Results available

Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas

NCT01595321
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Cyclophosphamide, GVAX Pancreas Vaccine, Stereotactic Body Radiation, FOLFIRINOX
Drug · Biological · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 76 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Sep 29, 2026, 11:15 PM EDT
Completed Not applicable Interventional Results available

Impact of Vitamin D Repletion in Hemodialysis Patients

NCT01175798
View directory record Official record
Conditions
Vitamin D Deficiency, End-stage Renal Disease
Interventions
Cholecalciferol
Drug
Lead sponsor
Mehrotra, Anita, M.D.
Individual
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Sep 29, 2026, 11:15 PM EDT
Terminated Phase 3 Interventional Results available

Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders

NCT02266433
View directory record Official record
Conditions
DeQuervains Tenosynovitis, Lateral Epicondylitis, Tennis Elbow, Trigger Finger, Tenosynovitis, Inflammatory Disease
Interventions
Ketorolac, Dexamethasone
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Sep 29, 2026, 11:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluating a Telephone-Based Smoking Cessation Program Among People in the Military (The AFIII Study)

NCT00632411
View directory record Official record
Conditions
Smoking, Smoking Cessation
Interventions
Nicotine Patch, Tobacco Quit Line Program
Drug · Behavioral
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
1,298 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
2
States / cities
Memphis, Tennessee • Lackland Air Force Base, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Sep 29, 2026, 11:15 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

NCT04452591
View directory record Official record
Conditions
Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
Interventions
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside
Biological · Other
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
45
States / cities
Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Sep 29, 2026, 11:15 PM EDT
Completed Not applicable Interventional

Investigating the Effectiveness of Intradialytic Massage on Cramping in Dialysis Patients

NCT01944280
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
massage
Other
Lead sponsor
Catherine Sullivan
Other
Eligibility
18 Years to 90 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Sep 29, 2026, 11:15 PM EDT
Active, not recruiting Not applicable Interventional

Testing Counseling and Mobile Health Interventions to Improve Physical Activity and Diet Quality in Survivors of Childhood Cancer

NCT05075759
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Behavioral Intervention, Survey Administration, Interview
Behavioral · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 54 Years
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Memphis, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 29, 2026, 11:15 PM EDT
Completed Phase 1 Interventional Results available

An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma

NCT01137006
View directory record Official record
Conditions
Malignant Melanoma
Interventions
IMC-20D7S (Cohort 1A), IMC-20D7S (Cohort 2A), IMC-20D7S (Cohort 3A), IMC-20D7S (Cohort 4A), IMC-20D7S (Cohort 1B), IMC-20D7S (Cohort 2B), IMC-20D7S (Cohort 3B)
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Sep 29, 2026, 11:15 PM EDT
Completed Not applicable Interventional Results available

Pilot Trial of Abdominal Core Rehabilitation To Improve Outcomes After Ventral Hernia Repair

NCT05142618
View directory record Official record
Conditions
Ventral Hernia, Hernia, Herniorrhaphy, Abdominal Wall, Postoperative Period, Physical Therapy Modalities
Interventions
Supervised Physical Therapy, Post-operative Precautions
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 29, 2026, 11:15 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effect of Resistance Training on Tobacco-Related Cardiovascular Disease Risk

NCT01705951
View directory record Official record
Conditions
Smoking, Cardiovascular Disease Risk
Interventions
Resistance Training (RT), Nicotine Replacement Therapy (NRT)
Other · Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 35 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2012 · Synced Sep 29, 2026, 11:15 PM EDT
Completed Phase 1 Interventional

A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors

NCT03238027
View directory record Official record
Conditions
Solid Tumor, Metastatic Tumor, Locally Advanced Malignant Neoplasm, Unresectable Malignant Neoplasm
Interventions
Axatilimab, Durvalumab
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Scottsdale, Arizona • Baltimore, Maryland • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Sep 29, 2026, 11:15 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Functional MRI Before and After Treatment for Depression

NCT00896441
View directory record Official record
Conditions
Depression, Mood Disorders, Depressive Disorder
Interventions
Citalopram
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Sep 29, 2026, 11:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates

NCT04565353
View directory record Official record
Conditions
Influenza, Human
Interventions
Flu shot text messages
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
74,811 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Danville, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Sep 29, 2026, 11:15 PM EDT
Recruiting Not applicable Interventional

Radio- KO Radiotherapy for Knee Osteoarthritis Clinical Trial

NCT06887829
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Low dose radiotherapy, Sham comparator
Radiation · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 100 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 29, 2026, 11:15 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

NCT03491683
View directory record Official record
Conditions
Glioblastoma
Interventions
INO-5401, INO-9012, Cemiplimab, Radiation Therapy, Temozolomide
Biological · Radiation · Drug
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
21
States / cities
Duarte, California • Palo Alto, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 29, 2026, 11:15 PM EDT
Completed Early Phase 1 Interventional

Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas

NCT00795457
View directory record Official record
Conditions
Astrocytoma, Oligo-Astrocytoma, Glioma
Interventions
GAA/TT-peptide vaccine and poly-ICLC
Biological
Lead sponsor
Ian F. Pollack, M.D.
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 30, 2019 · Synced Sep 29, 2026, 11:15 PM EDT
Recruiting Phase 2 Interventional

Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma

NCT07221942
View directory record Official record
Conditions
Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma, Advanced Urothelial Carcinoma
Interventions
Enfortumab vedotin, Pembrolizumab
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 29, 2026, 11:15 PM EDT
Recruiting Not applicable Interventional

Examining Whether Project Support Works

NCT06963554
View directory record Official record
Conditions
Parent-Child Relations, Parenting Self Efficacy, Child Mental Health
Interventions
Project Support, Case Management Services
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
6 Years to 13 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 29, 2026, 11:15 PM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

A Dosing Study of Hyperbaric Oxygen Therapy (HBOT) on Epigenetic Aging

NCT05297019
View directory record Official record
Conditions
Aging
Interventions
Hyperbaric Oxygen Therapy
Procedure
Lead sponsor
TruDiagnostic
Industry
Eligibility
40 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Florham Park, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Sep 29, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)

NCT02336230
View directory record Official record
Conditions
Grade B aGVHD, Grade C aGVHD, Grade D aGVHD
Interventions
remestemcel-L
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
2 Months to 17 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
20
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Sep 29, 2026, 11:15 PM EDT